Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 20, Issue 17, 2002, Pages 3605-3616

  Douillard, Jean Yves ^a   Hoff, Paulo M ^a   Skillings, Jamey R ^a   Eisenberg, Peter ^a   Davidson, Neville ^a   Harper, Peter ^a   Vincent, Mark D ^a   Lembersky, Barry C ^a   Thompson, Seth ^a   Maniero, Antonella ^a   Benner, Steven E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANXIOLYTIC AGENT; BILIRUBIN; FLUOROURACIL; FOLINIC ACID; GROWTH FACTOR; SEROTONIN 3 ANTAGONIST; UFT;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; QUALITY OF LIFE; SURVIVAL RATE; TEGAFUR; UNITED STATES; URACIL;

EID: 0036731818     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.04.123     Document Type: Article

References (53)

1. Cancer statistics, 2001
2. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer
3. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
4. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study
5. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
6. Mature results from three large controlled studies with raltitrexed ('Tomudex')
7. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT™ in combination with leucovorin (LV) in patients with metastatic colorectal cancer
8. Randomized comparative study of ORZEL® (oral uracil/tegafur (UFT™) plus leucovorin (LV)) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer
9. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
10. A phase III trial (S014796) of XELODA™ (capecitabine) in previously untreated advanced/metastatic colorectal cancer
11. A phase III study of 5-fluorouracil (5FU) versus 5FU plus leucovorin (LV) versus 5FU plus interferon A-2b (IFN) in patients with advanced colorectal cancer (CRC)
12. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study
13. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
14. The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: Results of a phase III trial
15. Folinic acid does improve 5-fluorouracil activity in vivo: Results of a phase III study comparing 5-fluorouracil to 5-fluorouracil and folinic acid in advanced colon cancer patients
16. Fluorouracil as monotherapy or in combination with folic acid in the treatment of metastatic colorectal carcinoma
17. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
18. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
19. Analogs of pyrimidine nucleosides
20. Studies on coadministration of uracil or cytosine on antitumor activity of FT-207 or 5-FU derivatives
21. 5-FU, FT-207 and uracil concentrations in the serum and tissues of patients with cervical cancer after UFT oral administration
22. Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil
23. Activation of ftorafur [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil] to 5-fluorouracil and gamma-butyrolactone
24. Metabolic activation of ftorafur [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil]: The microsomal oxidative pathway
25. Hydroxylated metabolites of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in rats and rabbits
26. Human urinary metabolites of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur)
27. Report on nationwide pooled data and cohort investigation in UFT phase II study
28. Phase II trial of UFT in advanced colorectal and gastric cancer
29. Augmentation of the chemotherapeutic effectiveness of UFT, a combination of tegafur [1-(2-tetrahydrofuryl)-5-fluorouracil] with uracil, by oral 1-leucovorin
30. 5-Fluorouracil prodrug: Role of anabolic and catabolic pathway modulation in therapy of colorectal cancer
31. Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation
32. UFT modulated with leucovorin in advanced colorectal cancer: Oncopaz experience
33. Phase I study of UFT plus leucovorin in advanced colorectal cancer: A double modulation proposal
34. Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer: A phase II study
35. Uracil and tegafur modulated with leucovorin: An effective regimen with low toxicity for the treatment of colorectal cancer
36. Tratamiento prolongado con UFT y bajas dosis de leucovorin oral: Estudio fase I
37. UFT plus oral folinic acid as therapy for metastatic colorectal cancer in older patients
38. Tegafur-uracil (UFT) plus folinic acid in advanced rectal cancer
39. A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer
40. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-Day schedule
41. A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin
42. Phase II study of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal cancer
43. A comparison of two quality of life questionnaires for cancer clinical trials: The Functional Living Index-Cancer (FLIC) and the Quality of Life Questionnaire Core Module (QLQ-C30)
44. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2′-tetrahydrofuryl)-5-fluorouracil
45. A prospective randomised comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study
46. Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer
47. A randomised study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma
48. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer
49. Xeloda tablets: Adverse reactions
50. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study
51. Mini-meta-analysis of toxicity of full dose Mayo regimen (FUFA) from two randomized controlled trials (RCTs): A concern about dose
52. Phase I/II study of oral uracil/tegafur (UFT®) leucovorin and irinotecan in patients with advanced colorectal cancer
53. A phase I study of oral uracil/tegafur (UFT) plus leucovorin (LV) combined with oxaliplatin in patients with metastatic colorectal cancer (CRC)